Sanofi uses voucher to speed diabetes combo review

Sanofi (Euronext:SAN; NYSE:SNY) submitted an NDA to FDA along with a Priority Review voucher seeking expedited review of the company's fixed-dose combination of glucagon-like peptide-1 receptor ( GLP-1R) agonist lixisenatide ( ZP10) and Lantus insulin glargine to treat Type II diabetes.

The NDA submission triggered a $20 million milestone payment from Sanofi to partner Zealand Pharma A/S (CSE:ZEAL). Sanofi said it is still considering a proprietary name for the combo, which Zealand called LixiLan. ...